Aldeyra Therapeutics is a biotechnology company focused on developing innovative medicines aimed at improving the lives of patients suffering from immune-mediated diseases. These are conditions where the immune system mistakenly attacks the body's own cells, leading to various health issues. The company operates in the healthcare and pharmaceutical market, primarily targeting patients with specific medical needs that are not adequately addressed by current treatments.

Aldeyra's primary clients are patients who suffer from conditions such as dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy (PVR). PVR is a serious eye condition that can lead to blindness, affecting approximately 4,000 patients annually in the United States. The company is also working on treatments for other retinal and systemic inflammatory diseases.

The business model of Aldeyra Therapeutics revolves around the research, development, and commercialization of new drug therapies. They invest heavily in clinical trials to ensure the safety and efficacy of their drug candidates. Once these drugs receive regulatory approval, Aldeyra can bring them to market, either directly or through partnerships with larger pharmaceutical companies. This process allows them to generate revenue through the sale of their proprietary medicines.

Aldeyra makes money primarily through the sale of these next-generation therapies. Additionally, they may enter into licensing agreements or partnerships with other companies, which can provide upfront payments, milestone payments, and royalties based on the sales of their drugs.

In summary, Aldeyra Therapeutics is dedicated to creating and bringing to market new treatments that can significantly improve the quality of life for patients with immune-mediated diseases. Their focus on innovative drug development positions them as a key player in the biotechnology sector.

Keywords: biotechnology, immune-mediated diseases, drug development, clinical trials, dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, retinal diseases, systemic inflammatory diseases, pharmaceutical market.